Cocrystal Pharma Inc

8CC

Company Profile

  • Business description

    Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

  • Contact

    19805 North Creek Parkway
    BothellWA98011
    USA

    T: +1 877 262-7123

    E: [email protected]

    https://www.cocrystalpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    10

Stocks News & Analysis

stocks

AI stocks stumble amid growing safety fears

Warnings from Anthropic, OpenAI, and SpaceX are raising questions over the future of the AI buildout.
stocks

ASX miner raises dividend despite earnings miss

Dividend surprise boosts investor confidence.
stocks

Chart of the Week: BHP’s valuation hits historic levels

BHP and peers are trading as if the copper boom is here to stay.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.7011.800.13%
CAC 408,065.02121.91-1.49%
DAX 4025,304.06412.65-1.60%
Dow JONES (US)51,682.6495.40-0.18%
FTSE 10010,659.13157.01-1.45%
HKSE24,750.78146.490.60%
NASDAQ26,522.54104.250.39%
Nikkei 22565,018.95882.701.38%
NZX 50 Index13,739.1417.45-0.13%
S&P 5007,650.5012.740.17%
S&P/ASX 2008,731.201.20-0.01%
SSE Composite Index3,911.8736.270.94%

Market Movers